The U.S. Food and Drug Administration (FDA) has granted approval for Sanofi’s BTK inhibitor, a significant component of the company’s immunology strategy. This development...
Sanofi has announced a significant limitation in the supply of its cholesterol-lowering drug, Praluent, in China. This shortage is attributed to a sharp increase...